Tiziana Life Sciences PLC - London-headquartered biotechnology company - Is granted a US patent on the methods and use of anti-IL-6/IL-6 receptor monoclonal antibodies in Covid-19 as well as other pulmonary diseases. The patent is for the use of fully human monoclonal antibody, TZLS-501, for both preventative and therapeutic intervention in human diseases. Tiziana originally entered a worldwide exclusive licence with Novimmune SA in 2017, with the licence now currently maintained with Bristol Myers Squibb Co. The patent - number 10,759,862 - will be published by the US Patent & Trademark Office on September 1. "The grant of this additional patent on TZLS-501 is of particular significance for the potential treatment of Covid-19 and other pulmonary diseases such as acute respiratory distress syndrome," said Tiziana.
Current stock price: 158.75 pence
Year-to-date change: up more than 100%; 41.00p December 31
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
